Effect of oral contraceptives on lamotrigine levels depends on comedication

Acta Neurologica Scandinavica

Volumn 129, Issue 6, 2014, Pages 393-398

  Wegner, I ^a,b   Wilhelm, A J ^c   Lambrechts, D A J E ^d   Sander, J W ^a,e   Lindhout, D ^a,b  

^a STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d EPILEPSY CENTER KEMPENHAEGHE   (Netherlands)

^e UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Combination therapy; Dried blood spot; Epilepsy; Lamotrigine; Oral contraceptives; Pharmacokinetics; Serum concentration

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; VALPROIC ACID; ANTICONVULSIVE AGENT; TRIAZINE DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; EPILEPSY; FEMALE; HUMAN; MONOTHERAPY; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; BLOOD; BLOOD ANALYSIS; COMPUTER PROGRAM; DRUG COMBINATION; DRUG INTERACTION; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; YOUNG ADULT;

ADULT; ANTICONVULSANTS; BLOOD CHEMICAL ANALYSIS; CARBAMAZEPINE; CONTRACEPTIVES, ORAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; PROSPECTIVE STUDIES; SOFTWARE; TRIAZINES; YOUNG ADULT;

EID: 84897957773     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12197     Document Type: Article

References (25)

1. Sabers A, Buchholt JM, Uldall P, Hansen EL. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 2001;47:151-4.
2. Christensen J, Petrenaite V, Atterman J et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia 2007;48:484-9.
3. Wegner I, Edelbroek PM, Bulk S, Lindhout D. Lamotrigine kinetics within the menstrual cycle, after menopause, and with oral contraceptives. Neurology 2009;73:1388-93.
4. Vermeij TAC, Edelbroek PM. Robust isocratic high performance liquid chromatographic method for simultaneous determination of seven antiepileptic drugs including lamotrigine, oxcarbazepine and zonisamide in serum after solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci 2007;857:40-6.
5. Holford NHG. Wings for NONMEM Version 6.1.6 for NONMEM VI. http://wfn.sourceforge.net (accessed 12 June 2010).
6. Jonsson EN, Karlsson MO. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999;58:51-64.
7. Grasela TH, Fiedler-Kelly J, Cox E, Womble GP, Risner ME, Chen C. Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. J Clin Pharmacol 1999;39:373-84.
8. Vuciçeviç K, Miljkoviç B, Velickoviç R, Pokrajac M, Mrhar A. Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data. Ther Drug Monit 2007;29:781-8.
9. Bondareva IB, Jelliffe RW, Andreeva OV, Bondareva KI. Predictability of individualized dosage regimens of carbamazepine and valproate mono- and combination therapy. J Clin Pharm Ther 2011;36:625-36.
10. Garnett WR. Lamotrigine. Interaction with other drugs. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs, 5th edn. Philadelphia, PA: Lippincott Williams and Wilkins, 2002;380-8.
11. Green MD, Bishop WP, Tephly TR. Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides. Drug Metab Dispos 1995;23:299-302.
12. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, Miners JO. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 2006;34:1055-62.
13. Shenfield GM, Griffin JM. Clinical pharmacokinetics of contraceptive steroids. An update. Clin Pharmacokinet 1991;20:15-37.
14. Chen H, Yang K, Choi S, Fischer JH, Jeong H. Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17β-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy. Drug Metab Dispos 2009;37:1841-7.
15. Dickins M, Chen C. Lamotrigine. Chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs, 5th edn. Philadelphia, PA: Lippincott Williams and Wilkins, 2002;370-9.
16. Tomson T, Luef G, Sabers A, Pittschieler S, Öhman I. Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. Neurology 2006;67:1297-9.
17. Herzog AG, Blum AS, Farina EL et al. Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive use. Neurology 2009;72:911-4.
18. Correa T, Rodríguez I, Romano S. Population pharmacokinetics of valproate in Mexican children with epilepsy. Biopharm Drug Dispos 2008;29:511-20.
19. Jankovic SM, Milovanovic JR, Jankovic S. Factors influencing valproate pharmacokinetics in children and adults. Int J Clin Pharmacol Ther 2010;48:767-75.
20. De Haan GJ, Edelbroek P, Segers J et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 2004;63:571-3.
21. Sabers A. Algorithm for lamotrigine dose adjustment before, during, and after pregnancy. Acta Neurol Scand 2012;126:e1-4.
22. Tomson T, Battino D, Bonizzoni E et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011;10:609-17.
23. Spina E. Carbamazepine. Chemistry, biotransformation and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs, 5th edn. Philadelphia, PA: Lippincott Williams and Wilkins, 2002;236-46.
24. May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet 2003;42:1023-42.
25. Wegner I, Edelbroek P, de Haan GJ, Lindhout D, Sander JW. Drug monitoring of lamotrigine and oxcarbazepine combination during pregnancy. Epilepsia 2010;51:2500-2.